<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Chief Scientific Officer Robert W. Georgantas III, Ph.D.

Robert W. Georgantas III, Ph.D. is recognized as a leader of immunology translational science and strategy. He has served as Biodesix’s Chief Scientific Officer since February 2022, after more than two years as Senior Vice President of Research and Translational Science.

From 2014 to 2019, prior to joining Biodesix, Dr. Georgantas worked at AbbVie where he served as Director of Immunology Programs and Biomarkers within the Genomics Research Center of Excellence, a group of experts tasked with applying genetics, genomics, epigenetics, and metagenomics to inform the product pipeline primarily regarding new target discovery, biomarkers for clinical trials, and asset positioning. Dr. Georgantas spent the early part of his career as a faculty research associate at the Johns Hopkins School of Medicine, examining the roles and mechanisms that microRNAs play in hematopoietic stem cells, leukemia and lymphoma stem cells, and various leukemias. Dr. Georgantas also headed a program examining the role of microRNAs in drug resistance of leukemias and of pancreatic cancer.

After leaving academic research, Dr. Georgantas retained a teaching appointment at Johns Hopkins, in the Department of Biotechnology in the School of Advanced Academic Programs, where he taught graduate courses in human gene therapy, human molecular genetics, and advanced cellular Biology.

Dr. Georgantas completed his Ph.D. in pharmacology and molecular medicine at The Johns Hopkins University School of Medicine. He completed graduate studies at Illinois Institute of Technology and undergraduate studies at the University of Illinois Urbana-Champaign.

Dr. Georgantas enjoys giving his time as a coordinator and volunteer for organizations like the IGA Nephropathy Foundation of America, Special Olympics Maryland and One Brick.

Data-driven diagnostic solutions

Contact our team to learn more